These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 38940731)

  • 1. A Perspective on Interdicting in Protein Misfolding for Therapeutic Drug Design: Modulating the Formation of Nonlocal Contacts in α-Synuclein as a Strategy against Parkinson's Disease.
    Bergasa-Caceres F; Rabitz HA
    J Phys Chem B; 2024 Jul; 128(27):6439-6448. PubMed ID: 38940731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Downsized and Optimised Intracellular Library-Derived Peptide Prevents Alpha-Synuclein Primary Nucleation and Toxicity Without Impacting Upon Lipid Binding.
    Meade RM; Watt KJC; Williams RJ; Mason JM
    J Mol Biol; 2021 Dec; 433(24):167323. PubMed ID: 34695381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
    Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
    Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.
    Padilla-Godínez FJ; Ramos-Acevedo R; Martínez-Becerril HA; Bernal-Conde LD; Garrido-Figueroa JF; Hiriart M; Hernández-López A; Argüero-Sánchez R; Callea F; Guerra-Crespo M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
    Fonseca-Ornelas L; Eisbach SE; Paulat M; Giller K; Fernández CO; Outeiro TF; Becker S; Zweckstetter M
    Nat Commun; 2014 Dec; 5():5857. PubMed ID: 25524885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of formation of α-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease.
    Faria C; Jorge CD; Borges N; Tenreiro S; Outeiro TF; Santos H
    Biochim Biophys Acta; 2013 Aug; 1830(8):4065-72. PubMed ID: 23608058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
    Sharma SK; Priya S
    Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.
    Luna E; Luk KC
    FEBS Lett; 2015 Dec; 589(24 Pt A):3749-59. PubMed ID: 26505673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease as a member of Prion-like disorders.
    Herva ME; Spillantini MG
    Virus Res; 2015 Sep; 207():38-46. PubMed ID: 25456401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
    Tavassoly O; Lee JS
    FEBS Lett; 2012 Sep; 586(19):3222-8. PubMed ID: 22771474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early stages for Parkinson's development: alpha-synuclein misfolding and aggregation.
    Yu J; Lyubchenko YL
    J Neuroimmune Pharmacol; 2009 Mar; 4(1):10-6. PubMed ID: 18633713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
    Gonçalves PB; Sodero ACR; Cordeiro Y
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
    Tóth G; Gardai SJ; Zago W; Bertoncini CW; Cremades N; Roy SL; Tambe MA; Rochet JC; Galvagnion C; Skibinski G; Finkbeiner S; Bova M; Regnstrom K; Chiou SS; Johnston J; Callaway K; Anderson JP; Jobling MF; Buell AK; Yednock TA; Knowles TP; Vendruscolo M; Christodoulou J; Dobson CM; Schenk D; McConlogue L
    PLoS One; 2014; 9(2):e87133. PubMed ID: 24551051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling.
    Berrocal R; Vasquez V; Rao Krs S; Gadad BS; Rao KS
    Mol Neurobiol; 2015; 51(3):1417-31. PubMed ID: 25139280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating the Amyloidogenesis of α-Synuclein.
    Sivanesam K; Andersen NH
    Curr Neuropharmacol; 2016; 14(3):226-37. PubMed ID: 26517049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy.
    Shahnawaz M; Mukherjee A; Pritzkow S; Mendez N; Rabadia P; Liu X; Hu B; Schmeichel A; Singer W; Wu G; Tsai AL; Shirani H; Nilsson KPR; Low PA; Soto C
    Nature; 2020 Feb; 578(7794):273-277. PubMed ID: 32025029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.